Independence County, Arkansas v. Pfizer, Inc.

CourtCourt of Appeals for the Eighth Circuit
DecidedJanuary 5, 2009
Docket08-1491
StatusPublished

This text of Independence County, Arkansas v. Pfizer, Inc. (Independence County, Arkansas v. Pfizer, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eighth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Independence County, Arkansas v. Pfizer, Inc., (8th Cir. 2009).

Opinion

United States Court of Appeals FOR THE EIGHTH CIRCUIT ________________

No. 08-1491 ________________

Ashley County, Arkansas; Benton * County, Arkansas; Cleburne * County, Arkansas; Faulkner * County, Arkansas, * * Plaintiffs, * * Independence County, Arkansas; * Chicot County, Arkansas; Conway * County, Arkansas; Cross County, * Arkansas; Fulton County, * Arkansas; Jackson County, * Arkansas; Lawrence County, * Arkansas; Izard County, Arkansas; * Monroe County, Arkansas; Nevada * Appeal from the United States County, Arkansas; Pulaski County, * District Court for the Arkansas; Sevier County, Arkansas; * Eastern District of Arkansas. Sharp County, Arkansas; Stone * County, Arkansas; Woodruff * County, Arkansas; Union County, * [PUBLISHED] Arkansas, * * Plaintiff-Appellants, * * v. * * Pfizer, Inc.; PDK Labs, Inc.; * Warner Lambert Company, LLC; * Johnson & Johnson; Perrigo * Company; John Does, 1 through 10, * * Defendant-Appellees. * ________________

Submitted: September 22, 2008 Filed: January 5, 2009 ________________

Before RILEY, HANSEN, and MELLOY, Circuit Judges. ________________

HANSEN, Circuit Judge.

Twenty individual counties in Arkansas brought this civil suit against Pfizer, Inc., PDK Labs, Inc., Warner Lambert Company, LLC, Johnson & Johnson, Perrigo Company, and various John Does (collectively "Defendants"),1 each of whom manufactures or distributes products containing ephedrine or pseudoephedrine. The complaint sought compensation to recoup the costs expended by the counties in dealing with the societal effects of the methamphetamine epidemic in Arkansas, with liability premised on the use of the Defendants' products in the methamphetamine manufacturing process. Sixteen of the counties (collectively "Counties") appeal the district court's2 order granting the Defendants' motion for judgment on the pleadings under Rule 12(c) of the Federal Rules of Civil Procedure, and we affirm.

1 The original complaint filed in Arkansas state court also named American Novelties; Cliff McQuay, Cliff McQuay, Jr. and Ellen McQuay, d/b/a/ Cliff McQuay Sales Company; and Jr. Food Mart of Arkansas, Inc. as defendants. These defendants were severed from the case when it was removed to federal court, and they were neither parties to the case in district court, nor are they parties to this appeal. 2 The Honorable William R. Wilson, United States District Judge for the Eastern District of Arkansas.

-2- I.

Because we are reviewing a judgment granted on the pleadings, we view all the facts pleaded by the Counties, the nonmovants, as true, and we make all reasonable inferences in the Counties' favor. Poehl v. Countrywide Home Loans, Inc., 528 F.3d 1093, 1096 (8th Cir. 2008). Methamphetamine is a highly addictive, synthetic drug that, according to the Counties, cannot be manufactured, or "cooked," without either ephedrine or pseudoephedrine. In Arkansas, methamphetamine is manufactured primarily in small toxic labs ("STLs") located in homes, tents, barns, or hotel rooms. According to the Counties, Arkansas has one of the highest numbers of STLs in the nation. The manufacturing process is dangerous, often resulting in explosions, chemical burns, chemical spills, and toxic fumes. The Counties allege that they have spent significant amounts of taxpayer dollars combating the manufacture of methamphetamine, including law enforcement costs to locate, eliminate, and clean up STLs where the methamphetamine is manufactured; prison and jail costs to house illegal users, dealers, and manufacturers; addiction treatment costs for users and addicts; costs to family service agencies for housing and treating children whose parents are arrested for methamphetamine-related charges; and costs for treating the physical side effects of methamphetamine use and exposure to its production.

The Defendants are manufacturers and distributors of over-the-counter cold and allergy medications containing either ephedrine or pseudoephedrine. None of the Defendants are retailers, nor do they sell the medications directly to the public. The Counties allege that the Defendants marketed and sold their products in Arkansas knowing that the products were being used illegally to manufacture methamphetamine.3 The Counties allege that the Defendants knew that their products

3 In their briefs to this court, the Counties allege that the Defendants intentionally targeted methamphetamine cooks by printing "pseudoephedrine" on the outside packaging of their cold medicines. These allegations were not included in the complaint, by which we are constrained in reviewing this dismissal on the pleadings.

-3- were being used illegally at least as early as 1986 when the federal Drug Enforcement Administration (DEA) began pushing for controls over the sale of products containing ephedrine or pseudoephedrine. During two different time periods, in 1995-1996 and in 1998-1999, the DEA placed restrictions on the importation of bulk ephedrine and tracked the sales of ephedrine and pseudoephedrine outside of "blister packs." According to the Counties, methamphetamine use and abuse declined dramatically during these time periods, but the Defendants allegedly fought to create loopholes in the regulations to continue reaping large profits in the sale of their products. In time, the Counties say, methamphetamine cooks learned how to exploit the loopholes, and methamphetamine use rose again.

The Counties claim that the Defendants knew of measures they could have voluntarily taken to reduce the availability of their products to methamphetamine cooks but consciously chose not to, fighting regulatory efforts in order to continue reaping large profits. The actions that the Defendants (who are manufacturers and wholesalers) allegedly should have voluntarily taken included directing the retailers to place the products behind the counter of retail stores; requiring the retailers to make retail purchasers sign for products when purchased from the retailer; educating the retailers and their employees about suspicious behavior by persons seeking to purchase the products for illegal use; requiring the retailers to lock the products in display cases; and requiring the retailers to limit the amount of product that could be purchased at retail by an individual during a specified period of time. These measures were eventually included in DEA regulations issued in 2005. The Counties also alleged that two of the Defendants, Warner Lambert and Pfizer, developed effective alternative cold medications that did not contain ephedrine or pseudoephedrine and that could not be used to produce methamphetamine, but that neither of them brought the alternative products to market.

In any event, the Counties do not dispute that the packaging complied with the federal Food and Drug Administration regulations.

-4- The Counties assert that the Defendants knew they were selling far more than the legitimate market for their products consumed as evidenced by the fact that the revenues of one of the Defendants, Perrigo, declined rapidly from $182 million to $30 million once regulations were passed in 2005 limiting access to the Defendants' products. The Counties also allege that the DEA sent letters to some of the Defendants warning them that their products were being used to make methamphetamine and that an executive from Pfizer admitted that the pharmaceutical industry was responsible for a portion of the methamphetamine problem in the United States. The Counties do not allege, however, that any of the Defendants violated any federal or state regulation governing the manufacture, distribution, packaging, or sale of their products.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Anza v. Ideal Steel Supply Corp.
547 U.S. 451 (Supreme Court, 2006)
Von R. Trimble, Jr. v. Asarco, Inc.
232 F.3d 946 (Eighth Circuit, 2000)
City of Philadelphia v. Beretta
277 F.3d 415 (Third Circuit, 2002)
City of Gary Ex Rel. King v. Smith & Wesson Corp.
801 N.E.2d 1222 (Indiana Supreme Court, 2003)
Bores v. Domino's Pizza, LLC
530 F.3d 671 (Eighth Circuit, 2008)
Stl 300 N. 4th, LLC v. Value St. Louis Associates
540 F.3d 788 (Eighth Circuit, 2008)
Poehl v. Countrywide Home Loans, Inc.
528 F.3d 1093 (Eighth Circuit, 2008)
HOK Sport, Inc. v. FC Des Moines, L.C.
495 F.3d 927 (Eighth Circuit, 2007)
In Re Western Iowa Limestone, Inc.
538 F.3d 858 (Eighth Circuit, 2008)
Delahanty v. Hinckley
564 A.2d 758 (District of Columbia Court of Appeals, 1989)
District of Columbia v. Beretta, U.S.A., Corp.
872 A.2d 633 (District of Columbia Court of Appeals, 2005)
Guaranty National Insurance v. Denver Roller, Inc.
854 S.W.2d 312 (Supreme Court of Arkansas, 1993)
First Commercial Trust Co. v. Lorcin Engineering, Inc.
900 S.W.2d 202 (Supreme Court of Arkansas, 1995)
Larson MacHine, Inc. v. Wallace
600 S.W.2d 1 (Supreme Court of Arkansas, 1980)
Dews v. Halliburton Industries, Inc.
708 S.W.2d 67 (Supreme Court of Arkansas, 1986)

Cite This Page — Counsel Stack

Bluebook (online)
Independence County, Arkansas v. Pfizer, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/independence-county-arkansas-v-pfizer-inc-ca8-2009.